Tepotinib

Tepotinib is a medication classified as a small molecule tyrosine kinase inhibitor (TKI). It specifically targets and inhibits the activity of the MET receptor tyrosine kinase, which is involved in promoting cancer cell growth and metastasis. Tepotinib is used in the treatment of certain types of cancers that harbor MET exon 14 skipping alterations, such as non-small cell lung cancer (NSCLC).

Indications

Treatment of adult patients with metastatic NSCLC whose tumors have a MET exon 14 skipping alteration and who have progressed on prior systemic therapy or are ineligible for chemotherapy.

Dosage

-The recommended dosage of tepotinib is typically 450 mg orally once daily, with or without food. -Dosage adjustments may be necessary based on individual patient factors such as tolerability and response to treatment.

Contra-Indications

Hypersensitivity to tepotinib or any component of the formulation.

Special Precautions

-Monitor for signs of interstitial lung disease (ILD) or pneumonitis; interrupt or discontinue treatment if these occur. -Assess liver function before starting tepotinib and monitor regularly during treatment, as hepatotoxicity may occur. -Use caution in patients with moderate to severe renal impairment; adjust dosage if necessary based on renal function tests.

Side Effects

Common side effects of tepotinib may include: -Peripheral edema -Nausea -Fatigue -Increased blood creatinine levels -Diarrhea

Drug Interactions

Tepotinib may interact with medications that are substrates of CYP3A4 or P-glycoprotein. Avoid concomitant use with strong CYP3A inhibitors or inducers.